153.87

3.11% 4.64

After Hours: 154.47 0.60 +0.39%

Revolution Medicines Inc (RVMD)

Overview News Price History Option Chain Financials Why RVMD Down? Discussions Forecast

Revolution Medicines Inc stock is traded at $153.87, with a volume of 1.58M. It is up +3.11% in the last 24 hours and up +5.59% over the past month. Revolution Medicines Inc is a clinical-stage precision oncology company developing novel targeted therapies for RAS-addicted cancers. The Company possesses structure-based drug discovery capabilities built upon chemical biology and cancer pharmacology know-how and proprietary technologies that enable the creation of small molecules tailored to unconventional binding sites. Its research and development pipeline comprises inhibitors that bind directly to RAS variants (RAS(ON) Inhibitors), designed to be used as monotherapy, in combination with other RAS(ON) Inhibitors and/or other therapeutic agents.

Previous Close:

$149.23

Open:

$150.4

24h Volume:

1.58M

Relative Volume:

0.53

Market Cap:

$32.71B

Revenue:

$742.00K

Net Income/Loss:

$-1.37B

P/E Ratio:

-21.75

EPS:

-7.0731

Net Cash Flow:

$-1.07B

1W Performance:

+3.11%

1M Performance:

+5.59%

6M Performance:

+94.97%

1Y Performance:

+274.29%

1-Day Range:

$149.67

$154.74

1-Week Range:

$141.44

$154.74

52-Week Range:

$34.00

$166.50

Revolution Medicines Inc Stock (RVMD) Company Profile

Name

Revolution Medicines Inc

Sector

Healthcare (1109)

Industry

Biotechnology (621)

Phone

650-481-6801

Address

700 SAGINAW DR, REDWOOD CITY, CA

Employee

883

Twitter

Next Earnings Date

2026-08-05

Latest SEC Filings

RVMD's Discussions on Twitter

Compare RVMD vs VRTX, REGN, ARGX, ALNY

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
RVMD Revolution Medicines Inc	153.87	32.71B	742.00K	-1.37B	-1.07B	-7.0731
VRTX Vertex Pharmaceuticals Inc	444.93	112.92B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	612.14	64.18B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	893.52	55.57B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	282.85	37.76B	4.29B	577.22M	641.34M	4.2086

Revolution Medicines Inc Stock (RVMD) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Mar-16-26	Resumed	Jefferies	Buy
Feb-27-26	Resumed	UBS	Buy
Nov-18-25	Initiated	Wolfe Research	Outperform
Nov-03-25	Initiated	RBC Capital Mkts	Outperform
Oct-21-25	Initiated	Mizuho	Outperform
Oct-16-25	Resumed	Stifel	Buy
Sep-12-25	Resumed	Raymond James	Strong Buy
Sep-05-25	Initiated	Truist	Buy
Aug-19-25	Initiated	Piper Sandler	Overweight
Aug-15-25	Initiated	Wells Fargo	Overweight
Jul-15-25	Initiated	Goldman	Buy
Jul-16-24	Reiterated	Needham	Buy
Jul-12-24	Initiated	Barclays	Overweight
Jul-08-24	Initiated	Jefferies	Buy
Apr-12-24	Reiterated	Needham	Buy
Apr-10-24	Upgrade	Raymond James	Outperform → Strong Buy
Mar-11-24	Initiated	Piper Sandler	Overweight
Jan-05-24	Upgrade	BofA Securities	Neutral → Buy
Jan-04-24	Initiated	Wedbush	Outperform
Nov-16-23	Initiated	Raymond James	Outperform
Feb-28-23	Upgrade	JP Morgan	Neutral → Overweight
Dec-14-22	Initiated	Needham	Buy
Oct-21-22	Initiated	Oppenheimer	Outperform
May-20-22	Initiated	BofA Securities	Neutral
Mar-01-22	Upgrade	Stifel	Hold → Buy
Sep-23-21	Initiated	Stifel	Hold
Aug-12-21	Downgrade	Goldman	Buy → Neutral
May-18-21	Initiated	Goldman	Buy
May-21-20	Initiated	H.C. Wainwright	Buy
Mar-09-20	Initiated	Cowen	Outperform
Mar-09-20	Initiated	Guggenheim	Buy
Mar-09-20	Initiated	JP Morgan	Neutral

View All

Revolution Medicines Inc Stock (RVMD) Latest News

Jun 13, 2026

Pancreatic Cancer Drug Milestone Affirms Why Revolution Medicines Inc. (RVMD) is a Hot Stock to Buy - Yahoo Finance

Jun 13, 2026

Revolution Medicines: Strong Data, Big Market (Rating Upgrade) - Seeking Alpha

Jun 13, 2026

Jun 12, 2026

Why is Revolution Medicines (RVMD) up 9.3% since last earnings report? - MSN

Jun 12, 2026

Number of shareholders of Revolution Medicines, Inc. – NASDAQ:RVMDW - TradingView

Jun 12, 2026

‘Pharma Bro’ Martin Shkreli Defends Revolution Medicines’ Pancreatic Cancer Study Data: ‘Progress Compounds’ - Stocktwits

Jun 12, 2026

Jun 11, 2026

Bernstein initiates coverage of Revolution Medicines (RVMD) with market perform recommendation - MSN

Jun 11, 2026

Daraxonrasib’s Phase 3 Pancreatic Cancer Survival Data Might Change The Case For Investing In RVMD - Yahoo Finance

Jun 11, 2026

Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Erasca, Inc. and Encourages Investors to Contact the Firm - GlobeNewswire Inc.

Jun 11, 2026

RVMD: Insider files Form 144 to sell 10,000 shares (NASDAQ: RVMD) - Stock Titan

Jun 11, 2026

Can Revolution Medicines Be a Game-Changer Stock? - Yahoo Finance

Jun 11, 2026

Jun 10, 2026

RVMD Maintained by Evercore ISI Group -- Price Target Raised to $220 - GuruFocus

Jun 10, 2026

Jun 09, 2026

Revolution Medicines Inc. Warrant (RVMDW) Edges Higher Amid Modest Trading ActivityFibonacci Entry Signals - newsline.com

Jun 09, 2026

Tango shares surge on early pancreatic cancer combination data - The Pharma Letter

Jun 09, 2026

UBS Maintains Revolution Medicines(RVMD.US) With Buy Rating, Maintains Target Price $175 - Moomoo

Jun 09, 2026

symbol__ Stock Quote Price and Forecast - CNN

Jun 09, 2026

Jun 08, 2026

Revolution Medicines (RVMD) Reports Promising Data on Vopimetost - GuruFocus

Jun 08, 2026

Tango Therapeutics Stock Soars 53% After ’Unprecedented’ Data on Pancreatic Cancer Treatment - Barron's

Jun 08, 2026

Revolution Medicines (RVMD) Strengthens PDAC Position with New D - GuruFocus

Jun 08, 2026

Is Revolution Medicines (RVMD) The Best Biotech Stock According to Billionaire Stanley Druckenmiller? - Insider Monkey

Jun 08, 2026